Changes in mRNA Expression by schedule-dependent combination of 5-FU and selumetinib

Anti-tumor effect of the combination between 5-FU and selumetinib was treatment schedule-dependent in BRAF or KRAS mutant CRC cells. Treatment of 5-FU for 2 days followed by selumetinib for another 2 days exhibited synergism for cell viability, whereas single or reversely combined treatment showed antagonism Microarray analysis revealed the distinct groups of genes underlying the efficacy for schedule-dependent treatment. The mRNA expression was analyzed in 5 groups of colo205 cells treated with DMSO(vehicle)(V), 5-FU (FX), selumetinib (AZD6244)(AX), 5-FU followed by selumetinib (FA), or selumetinib followed by 5-FU (AF). Triplicate samples were prepared for each treated group and vehicle-treated samples were used as control group.